The Pennsylvania-based biotech company, founded in 2012, creates monoclonal antibodies that target the unique form of Stem Cell Factor (SCF) driving the cascade of profibrotic cytokines. Their lead candidate, OpSCF, aims to treat fibrotic and remodeling diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, potentially preventing organ failure and death. Opsidio is currently in the preclinical stage of development.